CoreCap Advisors
NTLA icon

CoreCap Advisors’s Intellia Therapeutics NTLA Stock Holding History

CoreCap Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1
Closed -$17 – 3293
2026
Q2 		$17 Buy
+1
New +$14 ﹤0.01% 3149
2025
Q2 		– Sell
-29
Closed -$206 – 3079
2025
Q1 		$206 Buy
+29
New +$293 ﹤0.01% 2967

Other funds holding NTLA

Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Canal Insurance Company
Canal Insurance Company Greenville, South Carolina $426M AUM 30.47% 1-Year Est. Return
Elmwood Wealth Management
Elmwood Wealth Management Berkeley, California $416M AUM 11.87% 1-Year Est. Return
SteelPeak Wealth
SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return
Cyndeo Wealth Partners
Cyndeo Wealth Partners St. Petersburg, Florida $2.21B AUM 17.29% 1-Year Est. Return
Axxcess Wealth Management
Axxcess Wealth Management Carlsbad, California $2.44B AUM 16.42% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

CoreCap Advisors's NTLA Position: Q3 2026 in Review

CoreCap Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2026, closing a stake of 1 share — an estimated $17 sold.

CoreCap Advisors first reported a position in NTLA in Q1 2025 and held it in 2 quarters. The position peaked at $206 in Q1 2025. 45 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • CoreCap Advisors reported no remaining Intellia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • CoreCap Advisors sold 1 Intellia Therapeutics share in Q3 2026, an estimated $17.
  • CoreCap Advisors first reported a position in Intellia Therapeutics in Q1 2025 and held it in 2 quarters.
  • CoreCap Advisors's Intellia Therapeutics position peaked at $206 in Q1 2025.
  • 45 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.